Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Indicadores Ecográficos del Estado Nutricional y Resultados del Tratamiento en Pacientes Quirúrgicos en la Unidad de Cuidados Intensivos

6 de noviembre de 2026 actualizado por: Osijek University Hospital

Ultrasound Indicators of Nutritional Status and Treatment Outcomes in Surgical Patients in the Intensive Care Unit

Descripción general del estudio

Estado

Terminado

Condiciones

Descripción detallada

The surgical intensive care unit (ICU) provides continuous preoperative and postoperative monitoring of hemodynamically unstable, critically or potentially critically ill patients whose treatment requirements exceed the scope of the competent surgical department. The most common reasons for admission to the ICU are older age, multiple comorbidities, sepsis, demanding and high-risk surgery, and complications during the procedure. The literature increasingly reports that patients' nutritional status and clinical frailty are predictors of ICU treatment duration and outcome. The nutritional status (NS) of patients in intensive care units (ICUs) is assessed using clinical and laboratory indicators, including body mass index (BMI), the clinical frailty score, and hemoglobin and albumin levels. It is quantified by rating scales such as NRS (Nutritional Risk Screening) and MUST (Malnutrition Universal Screening Tool).

Frailty syndrome is defined as a patient's reduced capacity to tolerate changes in physical, physiological, and cognitive body functions. Given the reduction in the organism's physiological reserves, the patient becomes vulnerable to stressors and acute complications associated with the health condition. Patient frailty is correlated with aging, and age is among the most important determinants of frailty. In the intensive care unit, patient frailty is an important predictor of the duration and outcome of treatment, the development of complications during hospitalization, and, as noted above, the consumption of available resources. Assessment of patient frailty enables the appropriate selection of therapeutic procedures and provides overall support to the patient, aiming to achieve optimal treatment outcomes. Patient frailty can be measured using clinical scales; the most commonly used are the Clinical Frailty Scale (CSF) and the modified frailty index (mFI).

Ultrasound is a diagnostic tool that, due to its non-invasiveness and ease of use, is increasingly used to assess the patient's condition and changes during treatment. The most commonly measured ultrasound indicators in intensive care are the presence of effusion or blood in body cavities, flow through blood vessels, and measurement of distance for puncture purposes.

Ultrasound has recently been used to assess the patient's nutritional status by measuring muscle thickness and echogenicity, most often of the upper leg muscles, such as the quadriceps. Muscle cross-sectional area and the thickness of the adipose tissue above it are often measured.

Studies on nutritional status and its relationship with muscle echogenicity in the surgical patient population are rare.

The prospective observational study will include consecutive patients of both genders admitted to the Department of Intensive Care of the Clinical Hospital Center in Osijek. The expected number of subjects is 50. The study will be conducted after approval by the ethics committee of the Clinical Hospital Center in Osijek, and before inclusion, the investigator will obtain informed consent from the patient or a guardian. Patients who have had surgery on their right leg, on which muscle thickness and echogenicity will be measured, patients for whom informed consent is not obtained, and patients who are paraplegic will not be included in the study.

Demographic data will be recorded from medical records and the hospital information system for each individual subject. Patient demographics (age, gender), comorbidities, laboratory parameters (hemoglobin, albumin, lactate), reason and duration of intensive care unit hospitalization, and time required to wean the patient from mechanical ventilation will be recorded. Patient frailty will be assessed during an interview. For patients who are unable to provide information, information will be collected from family members. For the purposes of this study, the CFS will be used, which categorizes patients from 1 (very active, physically strong) to 9 (very sick, not expected to survive more than 6 months). The examiner will perform an ultrasound examination of the thigh muscles (m. rectus femoris, m. vastus intermedius, m. vastus medialis, m. vastus lateralis) with a linear ultrasound probe for each subject within 48 hours of admission to the intensive care unit (ICU), measure the thickness of the muscle and the fatty tissue immediately above it, and display the dimensions in mm. Muscle echogenicity will be expressed numerically using image analysis. Signal intensity will be calculated in a standard 5 × 5 mm area, equal across all images, using the ImageJ/Fiji software. The average of 3 ultrasound measurements will be calculated. In addition to ultrasound measurements, laboratory indicators of the patient's nutritional status are also important. Hemoglobin and serum albumin are most often associated with nutritional status. Their values are usually reduced in patients with clinical frailty, and the finding of anemia and hypoproteinemia of varying degrees is common in people with limited mobility, malnutrition, or in people with specific nutritional deficiencies, e.g., in liver cirrhosis. The values will be compared computationally with clinical indicators such as patient frailty, hemoglobin, albumin and the patient's status assessment obtained by rating scales (CSF, NRS).

Tipo de estudio

De observación

Inscripción (Actual)

59

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Osijek, Croacia, 31000
        • Osijek University Hospital; Medical Faculty

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

The study population will be randomly selected patients admitted to the intensive care unit after undergoing a surgical procedure. These surgical procedures include abdominal, neurosurgical, plastic-reconstructive, traumatological, thoracic, and maxillofacial surgeries. Patients will be included regardless of age, gender, or whether the procedure was emergency or elective.

Descripción

Inclusion Criteria:

  • postoperative intensive care

Exclusion Criteria:

  • surgery of the right leg
  • paraplegia, tetraplegia
  • refusal of the patient/guardian to participate in the research (informed consent not signed)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Surgical patients in the intensive care unit

The prospective observational study will include consecutive patients admitted to the Department of Intensive Care of the Clinical Hospital Center in Osijek. Patients will be randomly included, regardless of age, gender, or type of surgical procedure. The study will be conducted after approval by the ethics committee of the Clinical Hospital Center in Osijek, and before inclusion, the investigator will obtain informed consent from the patient or a guardian. Patients who have had surgery on their right leg, on which muscle thickness and echogenicity will be measured, patients for whom informed consent is not obtained, and patients who are paraplegic will not be included in the study.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Clinical Frailty Scale
Periodo de tiempo: Day 1 (within 24 hours from admission to the intensive care unit)

The Clinical Frailty Scale (CFS) is a 9-point clinician-judgment tool that assesses fitness-to-frailty (1=Very Fit, 9=Terminally Ill).

Day 1 (within 24 hours from admission to the intensive care unit)
Nutritional Risk Screening 2002
Periodo de tiempo: Day 1

The Nutritional Risk Screening 2002 (NRS-2002) is a rapid, validated tool designed by the European Society for Clinical Nutrition and Metabolism (ESPEN) to identify hospitalized patients at risk of malnutrition and requiring nutritional support. It calculates a total score (0-7) based on impaired nutritional status, disease severity, and age (≥70 years).

Day 1
Vastus intermedius thickness
Periodo de tiempo: Day 1

Vastus intermedius thickness measured by ultrasound and expressed in centimeters.

Day 1
Rectus femoris thickness
Periodo de tiempo: Day 1

Rectus femoris thickness measured by ultrasound and expressed in centimeters.

Day 1
Vastus medialis thickness
Periodo de tiempo: Day 1

Vastus medialis thickness measured by ultrasound and expressed in centimeters.

Day 1
Vastus lateralis thickness
Periodo de tiempo: Day 1

Vastus lateralis thickness measured by ultrasound and expressed in centimeters.

Day 1
Vastus intermedius echogenicity
Periodo de tiempo: Day 1

Muscle echogenicity will be analyzed using ImageJ software and expressed as the mean gray value.

Day 1
Rectus femoris echogenicity
Periodo de tiempo: Day 1

Muscle echogenicity will be analyzed using ImageJ software and expressed as mean grey value.

Day 1
Vastus medialis echogenicity
Periodo de tiempo: Day 1

Muscle echogenicity will be analyzed using ImageJ software and expressed as mean grey value.

Day 1
Vastus lateralis echogenicity
Periodo de tiempo: Day 1

Muscle echogenicity will be analyzed using ImageJ software and expressed as the mean gray value.

Day 1
Adipose tissue thickness
Periodo de tiempo: Day 1

Thickness of adipose tissue above quadriceps femoris muscle will be mesured by ultrasound and expressed in centimeters.

Day 1
Body mass index ˙(BMI)
Periodo de tiempo: Perioperative

Body Mass Index (BMI) is a screening tool that estimates body fat by dividing a person's weight in kilograms by the square of their height in meters (kg/m2)

Perioperative
Length of mechanical ventilation
Periodo de tiempo: One month from admission to the ICU.

Time from admission to the intensive care unit to the onset of spontaneous breathing. The time of admission to the intensive care unit is the start of mechanical ventilation. It lasts until extubation (removal of the endotracheal tube) and continuation of spontaneous breathing. It is expressed in hours.

Whether the patient is intubated again, these two ventilation times are added together.

One month from admission to the ICU.

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Haemoglobin
Periodo de tiempo: Day 1

Haemoglobin levels (g/L) will be measured in the blood sample.

Day 1
Albumin
Periodo de tiempo: Day 1

The albumin level (g/L) will be measured in the blood sample.

Day 1
C-reactive protein (CRP)
Periodo de tiempo: Perioperative

C-reactive protein (CRP) is a liver-produced protein that serves as a key biomarker of systemic inflammation, infection, and tissue damage. CRP (mg/L) will be measured in the blood sample.

Perioperative
Lactate
Periodo de tiempo: Day 1

Lactate (mmol/L) is an energy source and a metabolic product produced in muscles, red blood cells, and the brain during anaerobic metabolism. It serves as a marker of tissue oxygenation, with elevated blood levels suggesting potential metabolic stress.

Day 1

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Silla de estudio: Slavica Kvolik, prof., Osijek University Hospital; Medical Faculty Osijek

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de febrero de 2026

Finalización primaria (Actual)

13 de octubre de 2026

Finalización del estudio (Actual)

6 de noviembre de 2026

Fechas de registro del estudio

Enviado por primera vez

9 de marzo de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de marzo de 2026

Publicado por primera vez (Actual)

16 de marzo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

6 de noviembre de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • R1-13343

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Yes, upon request sent to principal investigator

Marco de tiempo para compartir IPD

After study publication.

Criterios de acceso compartido de IPD

Upon the reasonable request sent to principal investigator.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .